Aclaris Therapeutics (ACRS) announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis. Top line results are expected in the second half of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
- Wedbush bullish on Aclaris Therapeutics, initiates with an Outperform
- Aclaris Therapeutics initiated with an Outperform at Wedbush
- Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Drive Buy Rating